【葛兰素史克(GSK.US)、Inovio(INO.US)、Agios(AGIO.US)扎堆候审，美股创新药迎FDA审批窗口】上周，美国食品药品监督管理局（FDA）批准了多种新的和扩大的药物用途，其中最引人注目的是 ImmunityBio(IBRX.US)的 Anktiva 获批用于另一种膀胱癌。现在，所有人的目光都转向了 FDA 对治疗乙型肝炎、呼吸系统疾病和镰状细胞病的药物的决定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.